In summary, in this study, blocking NKCC1 activity with STS66 significantly reduced glioma cells proliferation, which is likely due to reduced intracellular K+ and Cl− concentration and prevents cell volume increase during G1 to S-phase of the cell cycle and reduces proliferation. The gene discussed is SLC12A2; the disease is glioma.